Research Identifies Protein Target That Improves Memory in Alzheimer's Mouse Model
Similar Articles
Researchers Identify Brain Cell Process That Removes Alzheimer's Plaques in Mice
Arginine Shows Promise in Reducing Alzheimer's Plaques in Animal Studies
Engineered Nanoparticles Show Promise in Restoring Brain Waste Removal in Alzheimer's Mouse Model
Researchers Restore Memory in Dementia Models by Fixing Mitochondrial Activity
Mayo Clinic Researchers Develop New Method to Tag Aging 'Zombie' Cells
Scientists have identified a strategy to improve learning and memory in a mouse model of Alzheimer's disease by blocking the protein PTP1B. This protein interacts with another that helps control the brain's immune cells responsible for clearing debris like amyloid-β (Aβ) plaques. The research team is now collaborating with a company to develop PTP1B inhibitors for medical applications.
Facts First
- Blocking the protein PTP1B improves learning and memory in a mouse model of Alzheimer's disease.
- PTP1B interacts with spleen tyrosine kinase (SYK), which helps control microglia, the brain's immune cells that clear debris like Aβ.
- Alzheimer's disease affects millions and is associated with risk factors like obesity and type 2 diabetes, for which PTP1B is also a therapeutic target.
- Current Alzheimer's therapies largely focus on reducing Aβ buildup, a peptide that can form plaques in the brain.
- The research lab is collaborating with DepYmed, Inc. to develop PTP1B inhibitors for several medical applications.
What Happened
Nicholas Tonks, a professor at Cold Spring Harbor Laboratory, along with graduate student Yuxin Cen and postdoctoral fellow Steven Ribeiro Alves, identified a strategy involving the blocking of the protein PTP1B. Their research shows this approach can improve learning and memory in a mouse model of Alzheimer's disease. PTP1B, which Professor Tonks discovered in 1988, interacts with the protein spleen tyrosine kinase (SYK). SYK helps control microglia, the brain's immune cells responsible for clearing debris such as excess amyloid-β (Aβ).
Why this Matters to You
Alzheimer's disease affects millions of people, with rising case numbers and associated costs reaching into the trillions. This research points to a potential new therapeutic pathway that moves beyond the current focus on directly reducing Aβ buildup. If developed successfully, PTP1B inhibitors could offer a new treatment strategy for a disease with limited options. Furthermore, because PTP1B is also a target for metabolic disorders like obesity and type 2 diabetes—known risk factors for Alzheimer's—a single treatment might address multiple connected health concerns.
What's Next
The Tonks lab is collaborating with DepYmed, Inc. to develop PTP1B inhibitors for several medical applications. This partnership suggests the preclinical findings are being actively pursued for potential drug development. The next steps will likely involve further testing to confirm the safety and efficacy of these inhibitors before they can be evaluated in human clinical trials.